Axa
VKTX icon

Axa’s Viking Therapeutics VKTX Stock Holding History

Axa’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,432
Closed -$1.42M – 989
2025
Q2 		$1.42M Buy
53,432
+85
+0.2% +$2.24K ﹤0.01% 832
2025
Q1 		$1.29M Sell
53,347
-67
-0.1% -$2.12K ﹤0.01% 811
2024
Q4 		$2.15M Sell
53,414
-85
-0.2% -$4.85K 0.01% 743
2024
Q3 		$3.39M Buy
53,499
+15
+0% +$880 0.01% 646
2024
Q2 		$2.84M Buy
+53,484
New +$3.51M 0.01% 675

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Axa's VKTX Position: Q3 2025 in Review

Axa sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 53,432 shares — an estimated $1.42M sold.

Axa first reported a position in VKTX in Q2 2024 and held it in 5 quarters. The position peaked at $3.39M in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Axa reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 53,432 Viking Therapeutics shares in Q3 2025, an estimated $1.42M.
  • Axa first reported a position in Viking Therapeutics in Q2 2024 and held it in 5 quarters.
  • Axa's Viking Therapeutics position peaked at $3.39M in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.